Integra LifeSciences

IART

Market cap $1.5B

IART Hedge Fund Activity: Q1 2026 in Review

201 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q1 2026, worth a combined $705M — down 23% from $919M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new IART positions and 33 closed out — a net gain of 3 holders — while 62 added to existing stakes and 69 trimmed.

The largest buyer was Paradigm Capital Management Inc, adding an estimated $14.8M. The largest seller was J. Goldman & Co, exiting entirely with an estimated $15.4M sold.

• 201 institutional investors held Integra LifeSciences (IART) as of Q1 2026, down from 204 in Q4 2025.
• Funds reported $705M of Integra LifeSciences stock for Q1 2026, down 23% quarter-over-quarter.
• 36 funds opened new Integra LifeSciences positions in Q1 2026 and 33 closed out, a net change of +3 holders.
• The largest Integra LifeSciences buyer in Q1 2026 was Paradigm Capital Management Inc, an estimated $14.8M added.
• The largest Integra LifeSciences seller in Q1 2026 was J. Goldman & Co, an estimated $15.4M sold.

Based on aggregated 13F filings for Q1 2026.